Skip to Content
Merck
CN

A6850

Azelaoyl PAF

10 mg/mL in ethanol

Synonym(s):

1-O-Hexadecyl-2-O-(9-carboxyoctanoyl)-sn-glyceryl-3-phosphocholine, 1-O-Hexadecyl-2-azelaoyl-sn-glycero-3-phosphocholine, hexadecyl azelaoyl phosphatidylcholine

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C33H66NO9P
Molecular Weight:
651.85
UNSPSC Code:
12352200
PubChem Substance ID:
329770906
EC Number:
200-578-6
MDL number:
MFCD03412018
Form:
liquid
Quality level:
200

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

ZDFOCDTXDPKJKA-WJOKGBTCSA-N

InChI

1S/C33H66NO9P/c1-5-6-7-8-9-10-11-12-13-14-15-16-20-23-27-40-29-31(30-42-44(38,39)41-28-26-34(2,3)4)43-33(37)25-22-19-17-18-21-24-32(35)36/h31H,5-30H2,1-4H3,(H-,35,36,38,39)/t31-/m1/s1

SMILES string

[O-]P(OCC[N+](C)(C)C)(OC[C@]([H])(OC(CCCCCCCC(O)=O)=O)COCCCCCCCCCCCCCCCC)=O

form

liquid

concentration

10 mg/mL in ethanol

shipped in

wet ice

storage temp.

−20°C

Quality Level

200

Application

Azelaoyl PAF is a potent PPARγ agonist. Azelaoyl PAF has been used to investigate whether peroxisome proliferator-activated receptors gamma agonists could play a role in the treatment of Friedreich′s ataxia, a neurodegenerative disease due to frataxin deficiency.

Biochem/physiol Actions

Potent PPARγ agonist.

Features and Benefits

This compound is featured on the Nuclear Receptors (PPARs) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

pictograms

FlameExclamation mark
GHS02,GHS07

signalword

Danger

hcodes

H225,H319

Hazard Classifications

Eye Irrit. 2 - Flam. Liq. 2

Storage Class

3 - Flammable liquids

wgk

WGK 2

flash_point_f

57.2 °F - closed cup

flash_point_c

14 °C - closed cup

ppe

Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
SLBQ8056V
SLBN0718V
SLBH1471V
SLBB2278V
089K1316

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Daniele Marmolino et al.
Cerebellum (London, England), 8(2), 98-103 (2008-12-24)
Friedreich's ataxia is a neurodegenerative disease due to frataxin deficiency, and thus, drugs increasing the frataxin amount are excellent candidates for therapy. By screening Gene Expression Omnibus profiles, we identified records showing a frataxin response to the peroxisome proliferator-activated receptors

Related Content

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service